Exosome therapy is a regenerative treatment that uses exosomes — tiny cell-derived vesicles that carry proteins, lipids and genetic messages between cells. Rather than transplanting whole cells, it delivers these signalling packages to support tissue repair and modulate inflammation. It is an emerging modality that is not yet approved as a standard drug in most countries.
If you have been researching options for slow-healing joints, recovery after injury, or the broad goal of ageing well, you have probably come across the word “exosomes.” It appears alongside stem cells and PRP in longevity and regenerative circles, often with more enthusiasm than explanation. Whether you are weighing this up for yourself or looking into it on behalf of a parent, partner or older relative, the sensible starting point is the same: understand what an exosome actually is, what the evidence currently shows, and what a responsible clinic can and cannot promise.
This article defines exosome therapy as a standalone modality. We keep the detailed head-to-head against whole-cell treatment for a companion piece — see our comparison of exosomes vs. stem cells — and focus here on the essentials every prospective patient deserves before making a decision.
What are exosomes?
Exosomes are among the smallest of the body’s extracellular vesicles — membrane-wrapped parcels that cells release to communicate with one another. They typically measure between 30 and 150 nanometres, and they form inside cells within structures called multivesicular bodies before being released when those bodies fuse with the cell membrane, as described in the biogenesis literature.
What makes them interesting therapeutically is their cargo. Each exosome carries proteins, lipids and nucleic acids — including messenger and micro-RNA — drawn from the cell that produced it. Reviews of intercellular signalling describe exosomes as vehicles that transmit functional instructions to recipient cells, where that cargo can influence how the receiving cell behaves. In short, an exosome is a message, not a cell. This distinction sits at the heart of why exosome therapy is treated differently from cell-based approaches.
How is exosome therapy different from stem cell therapy and PRP?
The three are often mentioned together, but they work through different mechanisms. Exosome therapy delivers the signalling vesicles alone, without transplanting living cells; the aim is to supply the communication molecules that healthy cells release, so surrounding tissue receives repair and anti-inflammatory cues.
Stem cell therapy, by contrast, introduces whole living cells that can themselves respond to their environment and, in part, exert their effect by secreting vesicles like exosomes. PRP therapy uses a concentrate of the patient’s own platelets and their growth factors, prepared from a simple blood draw. Put simply: PRP concentrates your own blood-derived factors, stem cell therapy provides cells, and exosome therapy provides the cell-free signals. Each has a different evidence base and a different practical profile. Our sibling article on exosomes vs. stem cells walks through the trade-offs in full.
What conditions and goals is exosome therapy used for?
Exosome research spans a wide range of tissues rather than a single condition. A 2025 review identified 66 clinical trials of mesenchymal-cell-derived vesicles and exosomes registered between 2014 and 2024, investigating applications across the lungs, joints, skin, liver, nervous system and more.
In practice, people explore exosome therapy for goals such as musculoskeletal recovery, joint and soft-tissue support, skin and hair concerns, and general regenerative and longevity aims. The appeal is straightforward: if healthy cells communicate through these vesicles, then supplying them may, in principle, nudge tissue towards repair and lower inflammatory signalling. That is the rationale behind much of the current research interest.
It is important to be clear-eyed, though. Much of this work remains investigational, the trials vary widely in size and quality, and being studied for a condition is not the same as being proven for it. We do not present exosome therapy as a cure for any disease, and neither should any clinic. Where the evidence is genuinely preliminary, we say so.
Who typically considers exosome therapy?
There is no single profile. Some patients are active adults managing a stubborn injury; others are in their sixties or seventies and simply want to stay mobile and independent. Many enquiries come from adult children researching on behalf of an ageing parent, or from partners looking into options together.
Exosome therapy is not reserved for athletes or executives, and framing it that way does patients a disservice. What matters far more than lifestyle or budget is a proper clinical assessment: your history, your goals, and whether a regenerative approach is genuinely appropriate for your situation. For some people it will be; for others, a different path — or no intervention at all — is the honest recommendation.
What does an exosome therapy session involve?
A responsible pathway begins before any treatment. It starts with an individualised consultation and, where indicated, advanced diagnostics to establish your baseline and confirm suitability. Only then is a plan discussed.
Administration routes vary by clinical context and can include localised injection to a target area or intravenous infusion; the review literature notes infusion and inhalation as common routes in trials. Sessions themselves are usually short, and most patients return to normal activity quickly, though guidance depends on the individual and the area treated.
Because protocols are not yet standardised across the field, dosing and frequency should always be set by a clinician who has assessed you personally — not copied from a generic template. This is also why questions about the product itself matter: where it was sourced, how it was handled, and what quality controls sit behind it. Any clinic offering an identical “package” to everyone, sight unseen, is a warning sign rather than a reassurance. A considered plan, a clear explanation of the evidence, and a willingness to say no are far better signals of a trustworthy service.
How strong is the evidence, and is exosome therapy approved?
This is where honesty matters most. Exosome therapy is an emerging modality, and the evidence base — while growing — is still maturing. The United States Food and Drug Administration states plainly that there are currently no FDA-approved exosome products, and has reported serious adverse events in patients treated with unapproved products marketed as containing exosomes. Regulatory status differs between countries, and much clinical use worldwide takes place outside a formal drug approval.
None of this means the science is not promising — it means expectations must be calibrated to what the data actually support, and treatment must happen under proper medical oversight with informed consent.
“Exosome therapy is one of the most promising areas in regenerative medicine, but promise is not the same as proof. We treat it as one considered option within a carefully assessed protocol, never a guaranteed cure, and we are candid with every patient about what today’s evidence can and cannot support,” says Dr. Natalie Lindemann, Clinical Director (Global) at Holina Global.
Exosome Therapy at Holina Clinic
Holina Clinic offers exosome therapy as part of its regenerative medicine services, delivered on-site across our Koh Phangan and Khao Yai campuses in Thailand. We approach it as a clinical decision, not a menu item.
Every patient begins with an individualised clinical assessment. We take a full history, discuss your goals honestly, and — where appropriate — use diagnostic testing to understand your baseline before any treatment is recommended. If exosome therapy is not the right fit, we will say so.
Where it is appropriate, exosome therapy is sometimes considered alongside other regenerative modalities we offer, such as stem cell therapy and PRP, as part of a personalised protocol shaped around the individual rather than a fixed formula. Because the field is still evolving, our clinicians set the plan case by case and keep patients fully informed about the current state of the evidence. Whether you are exploring this for yourself or for a family member, the first step is a conversation — you can contact our clinical team to ask questions and understand whether an assessment makes sense for your circumstances.
Frequently asked questions
What is exosome therapy in simple terms?
It is a treatment that uses exosomes — tiny cell-released vesicles carrying signalling molecules — to deliver repair and communication cues to tissue, without transplanting whole cells.
Are exosomes the same as stem cells?
No. Stem cells are living cells; exosomes are the small message-carrying packages that cells release. Exosome therapy supplies those signals rather than the cells themselves.
How is exosome therapy different from PRP?
PRP uses a concentrate of your own platelets and their growth factors from a blood draw. Exosome therapy uses cell-derived vesicles. The mechanisms and preparation differ, and each suits different situations.
Is exosome therapy FDA-approved?
No. The FDA states there are currently no FDA-approved exosome products, and regulatory status varies by country. It should only be received under proper medical oversight with informed consent.
What conditions is exosome therapy used for?
It is being studied across musculoskeletal, skin, respiratory, neurological and other applications. Being researched for a condition is not the same as being proven for it, and we make no disease-cure claims.
Is exosome therapy safe?
Safety depends heavily on product quality, sourcing and clinical oversight. Serious adverse events have been reported with unapproved products, which is why assessment, sourcing standards and medical supervision matter.
How is exosome therapy administered?
Depending on the clinical context, it may be given by localised injection or intravenous infusion. The appropriate route is decided by your clinician after assessment.
How many sessions will I need?
There is no universal answer. Because protocols are not yet standardised, the number and frequency of sessions should be set individually by a clinician who has assessed you.
Can exosome therapy be combined with other treatments?
In some cases it is considered alongside other regenerative modalities such as stem cell therapy or PRP, as part of a personalised plan. This is a clinical decision, not a fixed package.
Can I research exosome therapy for a family member?
Yes. Many enquiries come from people looking into options for a parent, partner or older relative. The starting point is the same for everyone: an individual assessment of suitability.
Does Holina Clinic offer exosome therapy?
Yes, on-site across our Koh Phangan and Khao Yai campuses, following an individualised clinical assessment. You are welcome to contact our team to discuss whether it is appropriate for you.
Clinically reviewed by Dr. Natalie Lindemann — Clinical Director, Holina Global · Last reviewed 20 July 2026.
